1.The analgesic effect of combination of low-flow rate oxygen inhalation with intravenous mannitolinjection for patients after nasal operation
Xiaoli ZHAO ; Qiuhua HUANG ; Lin SHEN ; Guangzhen PAN ; Li WU ; Huiping QI
Chinese Journal of Practical Nursing 2008;24(11):45-46
Objective To describe the analgesic effect of low-flow rate oxygen inhalation with intravenous mannitol injection for patients after nasal operation and seek for effective method for allevia-tion of pain.Methods 160 patients were divided into group A,B,C and D with 40 cases in each group.Group A received intravenous injection of 125 ml of 20%mannitol and group B got low-flow rate oxygen inhalation through nasal canulas.While group C were given the combination of treatment in that of group A and group B.Group D was named the control group and only adopted routine nursing.The pain alleviation effect was observed by McGill pain evaluation method.Results The score of pain in group C was lower than those in group A and B.While the scores of pain in group A and B were lower than that in group D(P<0.01).Conclusion The nasal swelling in group C lightened compared with those of group B (P<0.01)and group A(P<0.05).The nasal swelling in group A was lighter than that of group D but no difference Was seen between group B and group D
2.Effect of Ibudilast on the quality of life of patients with steroid resistant allergic rhinitis:a randomized,double blind,controlled study
Hong LUO ; Xiaoling LIU ; Zezhang TAO ; Nengbing YAN ; Guangzhen PAN ; Yan JIANG ; Ye YU ; Jiangping LI
Chinese Archives of Otolaryngology-Head and Neck Surgery 2006;0(11):-
OBJECTIVE To assess the effect of Ibudilast on the quality of life (QOL) of patients with steroid resistant allergic rhinitis.METHODS A randomized,double-blind,placebo-controlled study was carried out with Ibudilast in 66 patients with the steroid resistant allergic rhinitis.QOL was measured with Short-Form Health Survey (SF-36) questionnaire (Chinese version).Ibudilast (10rag twice daily,34 patients),placebo (32 patients) was given for 3 weeks. The SF-36 questionnaire was administered at the start of treatment and after 3 weeks of treatment.Sings and Symptom-medication scores were measured daily during the study.RESULTS There were no significant differences between the Ibudilast and placebo group in terms of sings and symptoms or QOL scores before study.After 3 weeks of treatment,symptoms scores were significantly decreased and QOL scores significantly improved in the Ibudilast group compared with those in placebo group (both P